Changes in cell proliferation and apoptosis during local progression of prostate cancer

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1135-1139

  Kaibuchi, Toshimitsu ^a   Furuya, Yuzo ^b   Akakura, Koichiro ^a   Masai, Motoyuki ^b   Ito, Haruo ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Ki 67; Local progression; Prostate cancer

Indexed keywords

HORMONE; KI 67 ANTIGEN;

APOPTOSIS; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

APOPTOSIS; BIOPSY; CELL DIVISION; CHLORMADINONE ACETATE; DIETHYLSTILBESTROL; DISEASE PROGRESSION; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0034011850     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Catalona WJ and Scott WW: Carcinoma of the prostate. J Urol 119: 1-8, 1978.
2. Walsh PC: The natural history of localized prostate cancer: a guide to therapy. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds): Campbell's Urology, 7th ed. Philadelphia: WB Saunders 2539-2546, 1998.
3. Shimazaki J, Isaka S and Akimoto S et al: Mechanism of relapse in prostate cancer. Akt Urol 21: 22-24, 1990.
4. Schroder FH: Endocrine treatment of prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's Urology, 7th ed. Philadelphia: WB Saunders 2627-2644, 1998.
5. Furuya Y, Akimoto S and Akakura K et al: Response of prostate specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol Int 60: 28-32, 1998.
6. Aalatomaa S, Lipponen P and Vesalainen S et al: Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 32: 410-415, 1997.
7. Mcloughlin J, Foster CS and Price P et al: Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Brit J Urol 72: 92-97, 1993.
8. Cattoretti G, Becker MH and Key G et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357-363, 1992.
9. Isaacs JT, Furuya Y and Berges R: The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 5: 391-400, 1994.
10. Gleason DF, Mellinger GT and the veterans administration cooperative urological research group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64, 1974.
11. Cox DR: Regression models and life tables. J R Stat Soc 34: 187-220, 1972.
12. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
13. Sugihara S, Nakashima O and Jojiro M et al: The morphologic transition in hepatocellular carcinoma. Cancer 70: 1488-1492, 1992.
14. Whittermore AS, Keller JB and Betensky R: Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? J Natl Cancer Inst 83: 1231-1235, 1991.
15. Ohki T, Akakura K and Ueda T et al: Changes in histologic grade and argyrophilic nucleolar organizer regions during progression of prostate cancer. Jpn J Clin Oncol 26: 82-87, 1996.
16. Gerdes J, Schwab U and Lemke H et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983.
17. Gerdes J, Lemke H and Baish H et al: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
18. Stapleton AMF, Zbell P and Kattan MW et al: Assessment of the biologic markers p53, ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82: 168-175, 1998.
19. Aihara M, Truong LD and Dunn JK et al: Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 25: 797-801, 1994.
20. Stattin P, Westin P and Damber JE et al: Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Brit J Cancer 77: 670-675, 1988.